ArticleFrontiers in public health2025
Getting ahead of the ageing curve: learning from EU experiences for a healthier demographic transition.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advanced Drug Delivery Strategies in Geriatric Patients with Polypharmacy: Integrating Pharmacokinetics, Personalized Medicine, and Emerging Technologies.Journal of clinical medicine · 2026Review
- Excess Mortality as the Primary Mediator of COVID-19's Impact on Life Expectancy in Europe: A Multilevel Longitudinal Analysis of Regional Disparities.Medicina (Kaunas, Lithuania) · 2026Article
- Exploring the Therapeutic Effect ofNutrients · 2026Article
- Thermogenic adipose tissue in older adults with obesity: a narrative review of mechanisms, brown fat resistance, and the translational relevance of exercise and nutrition.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population ageing is accelerating worldwide, with one in six people projected to be over 60 by 2030. This demographic shift is already evident in Europe, with slower life-expectancy gains, widening healthspan-lifespan gaps, and growing labour shortages. In this paper, we examine global projections, country-level disparities, evidence from economics, geroscience and public health to assess the conditions under which longevity can generate a net social dividend. Our analysis highlights recent advances in ageing research, including stem-cell, epigenetic and anti-inflammatory interventions, as well as meta-research efforts to promote community-driven consensus on strategic geroscience problems. Translating these insights into societal benefits require regulatory recognition of ageing as a treatable condition, equitable access to innovation, and living-lab ecosystems that connect bench discoveries to health and social care. Using fiscal modelling, we show that disability-driven expenditure could rise by as much as 2.7% of EU GDP annually by 2070, unless offset by slower biological ageing or managed migration. Finally, we suggest that European experiences, particularly from the Iberian Peninsula, can inform South American countries now entering rapid demographic transition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.